Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517127 | 1.00 | MAPT (0.50) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL4517619 | 1.00 | MAPT (0.50) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL1063470 | 0.87 | CYP2C9 (0.62) | MAPTKMT2APTPN1CYP2C9 | |
| SCHEMBL4539683 | 0.87 | CYP2C9 (0.62) | MAPTKMT2APTPN1CYP2C9 | |
| SCHEMBL4167158 | 0.87 | CYP2C9 (0.62) | MAPTKMT2APTPN1CYP2C9 | |
| SCHEMBL14286797 | 0.84 | MAPT (0.48) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL31619475 | 0.84 | CES2 (0.52) | CYP1A2PTPN1ALDH1A1TSHRCES1 | |
| SCHEMBL27608748 | 0.82 | PDK1 (0.51) | KMT2AHDAC1HDAC2ALDH1A1CYP2C9 | |
| SCHEMBL1822224 | 0.82 | MAPT (0.63) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL4737624 | 0.82 | MAPT (0.47) | MAPTKMT2ACYP2C19HIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101380317-A | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV (CN) | 2009-03-11 | — | — | CN | claimed |
| US-4411974-A | FOR NEGATIVE TONERS | XEROX CORPORATION (US) | 1983-10-25 | — | — | US | claimed |
| EP-4524216-B1 | INK COMPOSITION, PRODUCTION METHOD THEREOF, COMPOSITE PREPARED THEREFROM, AND ELECTRONIC DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025074305-A1 | N-(1-(AMINOMETHYL)CYCLOPROPYL)(ARYL OR HETEROARYL) CARBOXAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-04-10 | — | — | WO | disclosed |
| CN-119752839-A | Method for biologically catalytic synthesis of optically pure 2R-fluoro carboxylic acid and 2R-hydroxy carboxylic acid | 湖南师范大学 | 2025-04-04 | — | — | CN | disclosed |
| US-20250092275-A1 | INK COMPOSITION, PRODUCTION METHOD THEREOF, COMPOSITE PREPARED THEREFROM, AND ELECTRONIC DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-03-20 | — | — | US | disclosed |
| EP-4524216-A1 | INK COMPOSITION, PRODUCTION METHOD THEREOF, COMPOSITE PREPARED THEREFROM, AND ELECTRONIC DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd (KR) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023116774-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | 赛诺哈勃药业（成都）有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2014016766-A1 | GUANIDINE DERIVATIVES AS TRPC MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-01-30 | — | — | WO | disclosed |
| CN-101380317-B | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV PHARMACEUTICAL CO LTD | 2010-12-08 | — | — | CN | disclosed |
| US-20090291973-A1 | Novel Quinazoline Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-11-26 | — | — | US | disclosed |
| CN-101380317-A | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV (CN) | 2009-03-11 | — | — | CN | disclosed |
| EP-1951685-A1 | NOVEL QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007057447-A1 | NOVEL QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-05-24 | — | — | WO | disclosed |
| EP-1536798-A1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004019945-A1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| EP-1133488-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000031067-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-06-02 | — | — | WO | disclosed |
| US-5003074-A | N-fluorinated sulfonamides | CIBA-GEIGY CORPORATION (US) | 1991-03-26 | — | — | US | disclosed |
| US-4411974-A | FOR NEGATIVE TONERS | XEROX CORPORATION (US) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291973-A1 | Novel Quinazoline Derivatives and Their Medical Use | KCNA7, KCNN3, KCNQ5 | MAPT 2025/4885KMT2A 1926/4885CYP2C19 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.